Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.37 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR1D | P28221 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5606661 | 1.00 | KMT2A (0.43) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL5606437 | 0.86 | MEN1 (0.45) | KMT2AMEN1HTR1AHTR2ADRD2 | |
| SCHEMBL5606438 | 0.86 | MEN1 (0.45) | KMT2AMEN1HTR1AHTR2ADRD2 | |
| SCHEMBL6430991 | 0.85 | MEN1 (0.43) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL6694235 | 0.85 | MEN1 (0.43) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL6430994 | 0.85 | MEN1 (0.43) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL5613736 | 0.83 | MEN1 (0.41) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL5613738 | 0.83 | MEN1 (0.41) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL5158286 | 0.82 | HTR1A (0.49) | KMT2AMEN1FPR2TRPV4HRH4 | |
| SCHEMBL5158294 | 0.82 | HTR1A (0.49) | KMT2AMEN1FPR2TRPV4HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | claimed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| WO-2007026219-A2 | COMBINATIONS OF A 5-HT1B ANTAGONIST WITH A NORADRENALIN RE-UPTAKE INHIBITOR OR A SEROTONIN NORADRENALIN REUTAKE INHIBITOR FOR TREATING CNS CONDITIONS | PFIZER PRODUCTS INC. (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC | 2006-03-09 | — | — | US | disclosed |
| EP-1562908-A1 | QUINOLINE DERIVATIVES | Pfizer Products Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-6921760-B2 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. (US) | 2005-07-26 | — | — | US | disclosed |
| WO-2005053701-A1 | COMBINATION OF DOPAMINE AGONISTS AND ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER PRODUCTS INC. (US) | 2005-06-16 | — | — | WO | disclosed |
| US-6894062-B1 | Quinoline derivatives | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| WO-2004043929-A1 | QUINOLINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2004-05-27 | — | — | WO | disclosed |
| US-6627627-B2 | Useful as psychotherapeutic agents | PFIZER INC. | 2003-09-30 | — | — | US | disclosed |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | PFIZER INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2002046167-A1 | BENZYL (IDENE)-LACTAMS AND THEIR USE AS 5HT1-RECEPTOR LIGANDS | PFIZER PRODUCTS INC. (US) | 2002-06-13 | — | — | WO | disclosed |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER INC. | 2002-06-13 | — | — | US | disclosed |
| US-6403592-B1 | SEROTONIN REUPTAKE INHIBITORS | PFIZER INC | 2002-06-11 | — | — | US | disclosed |
| US-6380186-B1 | PSYCHOTHERAPEUTIC AGENTS | PFIZER INC | 2002-04-30 | — | — | US | disclosed |
| US-20020049211-A1 | Combination treatment for depression and anxiety | SOBOLOV-JAYNES SUSAN BETH (US) | 2002-04-25 | — | — | US | disclosed |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | PFIZER PRODUCTS INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1186318-A2 | Combination, for treating depression and anxiety, containing a 5HT1d receptor antagonist and aCNS penetrant NK-1 receptor antagonist | Pfizer Products Inc. (US) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091118-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | KMT2A 1683/4885MEN1 863/4885FPR2 835/4885 |
| US-20020049214-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | KMT2A 1959/4885MEN1 698/4885FPR2 887/4885 |
| US-20060052373-A1 | Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides | DRD2, OPRL1, SLC6A3 | KMT2A 3059/4885MEN1 2166/4885FPR2 2878/4885 |
| US-20020049211-A1 | Combination treatment for depression and anxiety | HTR1A, HTR1D, HTR5A | KMT2A 913/4885MEN1 1555/4885FPR2 1246/4885 |
| US-20020072519-A1 | Aralkyl and aralkylidene heterocyclic lactams and imides | MRPL21, ARAF, ARL1 | KMT2A 1683/4885MEN1 863/4885FPR2 835/4885 |
| US-20020091117-A1 | ARALKYL AND ARALKYLIDENE HETEROCYCLIC LACTAMS AND IMIDES | MRPL21, ARAF, ARL1 | KMT2A 1683/4885MEN1 863/4885FPR2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.